Consequently, BRD4 is targeted to inhibit NFκB transcriptional activity in a variety of cancer cells, and bromodomain inhibition has entered clinical trials [108,109,110,111,112] (NCT02543879). The gene discussed is NFKB1; the disease is cancer.